HC PUB.: 5838
Cat: H164-47/2007 (print publication)
ISBN: 978-0-662-69932-3 (print publication)
Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.
How the flu shot makes its way from the laboratory to the doctor's office
Step 1: Identifying the Virus
Step 2: Constructing the Strain and Reagents
Step 3: Production of Flu Vaccine
Step 4: Market Authorization
Step 5: Supply and Distribution of Flu Vaccine in Canada
Step 6: Post-Market Surveillance
The following publication describes the pathway for the development, regulation and distribution of the flu vaccine in Canada.
The flu virus strains circulating the globe change on a regular basis. Therefore the process for flu vaccine development starts off on a global scale annually. Each year in February, the World Health Organization (WHO) selects three influenza virus isolates which form the basis for flu vaccine production for the following fall and winter flu season.
In general, vaccines are produced by isolating or creating an organism (or part of one) that retains specific proteins called antigens which are responsible for inducing the body's immune response.
WHO collaborating centres oversee the construction of vaccine strains from the three selected influenza virus isolates. These organizations also produce special reagents to monitor the quality of vaccine production.
The vaccine strains and reagents are then distributed to flu vaccine manufacturers.
There are a handful of flu vaccine manufacturers responsible for running the production process and distributing the vaccine across North America and Europe.
The current manufacturing process involves the replication of vaccine strains in eggs. A few manufacturers use animal cells instead.
Clinical trials (studies) are conducted on humans to ensure that the vaccine is safe and effective.
Once the manufacturer has acquired sufficient scientific evidence that the vaccine is safe, effective and of suitable quality, a submission may be filed with Health Canada for market approval.
The Biologics and Genetic Therapies Directorate (BGTD) is the federal program within Health Canada's Health Products and Food Branch that is responsible for the regulation of new biological drugs, including vaccines.
Although they have an excellent safety record, vaccines are strictly regulated because they are unique in the fact that they are commonly administered to very large numbers of healthy people, including infants and children, in national immunization programs. Safety and quality are critical elements overseen by the BGTD.
Prior to market approval of a new vaccine, the manufacturer must file a New Drug Submission that demonstrates the safety, efficacy and quality of the flu vaccine to the BGTD. Vaccine manufacturers must supply facility information that outlines the method of manufacture in significant detail. An On-Site Evaluation is performed by BGTD scientists to assess the production process and the facility. Samples of at least three consecutive batches or "lots" of the vaccine are also tested in the laboratories of the BGTD to ensure consistency in the manufacturing process.
Results from human clinical trials must also be submitted, which provide evidence of the safety and efficacy profile of the product.
If, after the completion of the review, it is concluded that the benefits of the vaccine outweigh its risks, then the vaccine is issued a Notice of Compliance (NOC) and a Drug Identification Number (DIN), indicating that it is authorized for sale in Canada.
Following the issuance of an NOC, the manufacturer is required to submit samples of each lot to the BGTD for lot release testing. After confirming the safety and potency of each vaccine lot in its own laboratories, the BGTD issues a lot release letter authorizing the manufacturer to sell it in Canada.
Since the flu vaccine changes every year, manufacturers must send updated information on their manufacturing process with the selected strains as well as data from small clinical trials to demonstrate that the vaccine produced is able to stimulate the immune system of vaccinated individuals. The BGTD conducts an expedited review of the data and authorizes these modifications. This period typically occurs between July and September each year.
The Government of Canada, through Public Works and Government Services Canada (PWGSC), purchases flu vaccines on behalf of the provinces and territories. Long-term contracts are established with manufacturers and estimated requirements are provided several months in advance of the flu season, to secure adequate supply. The vaccine is available at public health clinics and doctor's offices in accordance with provincial and territorial influenza immunization programs. Flu vaccines are also available through private market contracts - and can be found at local pharmacies for those individuals seeking to buy them.
The Public Health Agency of Canada (PHAC) assists in the coordination and oversight of public market supply and distribution, in collaboration with PWGSC, BGTD (Health Canada), the manufacturers and Federal/Provincial/Territorial (FPT) committees. FPT Committees include the Canadian Immunization Committee that advises on immunization program planning and the Vaccine Supply Working Group that advises on vaccine supply issues across Canada.
The National Advisory Committee on Immunization (NACI) is an expert committee reporting to Canada's Chief Public Health Officer. NACI makes annual recommendations for the use of influenza vaccines in Canada including the identification of groups at risk of influenza for whom vaccine programs should be targeted.
PHAC carries out post-market surveillance of the flu vaccine, through the Canadian Adverse Events Following Immunization Surveillance System (CAEFISS). The CAEFISS includes a voluntary reporting system where local, provincial and territorial public health and health care providers can report adverse events they feel are associated with an immunization. Additionally there is an active paediatric hospital based surveillance network (Immunization Monitoring Program Active, or "IMPACT") that identifies selected serious adverse events that follow immunization.
Manufacturers are required to report to the BGTD all serious vaccination failures.
For more information on post-market surveillance for the flu vaccine, refer to the following website.
As the flu vaccine changes each year, all aspects of the flu vaccine, from strain identification, to production, regulatory authorization and distribution must be achieved within a time period of less than 8 months. As such significant international and national cooperation is required before the start of the flu shot campaign in November of each year.
The flu vaccine is a national resource that saves lives, can offset public health crises and contribute to quality of life in Canada.
Despite the promising advancements made in recent years, progress continues towards improving the manufacturing process, timeliness, availability and awareness of the flu vaccine. Health Canada plays a key role in ensuring that Canadians have access to safe and effective flu vaccines, through regulation.